Savara Inc (OQ:SVRA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 900 S Capital of Texas Hwy Ste 150
WEST LAKE HILLS TX 78746-5436
Tel: N/A
Website: savarapharma.com
IR: See website
<
Key People
Matthew Pauls
Chairman of the Board, Interim Chief Executive Officer
David L. Lowrance
Chief Financial Officer, Secretary
Badrul A. Chowdhury
Chief Medical Officer
Business Overview
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.
Financial Overview
For the six months ended 30 June 2020, Savara Inc revenues was not reported. Net loss decreased 27% to $24.8M. Lower net loss reflects Impairment of goodwill decrease from $7.4M (expense) to $0K, Research and development - Balancing val decrease of 6% to $18.3M (expense), Selling, general and administrative - Ba decrease of 20% to $4.7M (expense).
Employees: 42 as of May 7, 2020
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$49.10M as of Jun 30, 2020
Net annual income (TTM): -$68.93M as of Jun 30, 2020
Free cash flow (TTM): -$45.48M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 54,128,525 as of Aug 6, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.